IFEMA: Changes in Clinical Practices and organizational challenges, ESMO 2014 Legate

IFEMA: Changes in Clinical Practices and organizational challenges, ESMO 2014 Legate

After the communications presented at the European Society for Medical Oncology (ESMO 2014), the immunotherapy solidifies itself as an emerging therapy type, although there are still very important studies to be made in order to solidify its role in the practice.

Those targeted therapies to be one more part of the necessary therapeutic resources against cancer along with chemotherapy, radiotherapy and surgery. 19,859 professionals from around the world who specialise in oncology of which 1,585 were Spanish, have participated at ESMO 2014. Some of the challenges for personalised medicine to have an acceptable cost for the system are the multi-discipline or specialisation per types of tumours.4B

The medical advances presented at ESMO 2014, which had its end on the 30th of September and took place at IFEMA (Madrid), are no doubt going to have a bearing on treatment given to patients with cancer but will also require some organizational amendments in order to endure the sustainability of the healthcare system.

The last congress of the European Society for Medical Oncology gathered 19,859 experts from 131 countries around the world in the oncology field throughout the course of 5 days in Madrid. The figures top the attendance records of the last congress held in 2012 in Vienna by 23%. Hence, Spain has been the second in expert attendance – only after the United States of America- with 1,585 registered experts.